Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study.

Interstitial lung disease Modified Rodnan total skin thickness score Regression analysis Systemic sclerosis

Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
28 05 2019
Historique:
received: 10 12 2018
accepted: 15 05 2019
entrez: 30 5 2019
pubmed: 30 5 2019
medline: 28 5 2020
Statut: epublish

Résumé

Previous studies have shown the relationship between higher skin thickness score and the existence of organ involvements in systemic sclerosis (SSc). Here, we firstly investigated the correlation between skin thickness score and quantitative measurements of each organ involvement in Japanese patients with SSc. All Japanese SSc patients hospitalized to our clinic for initial evaluation of SSc were selected. Skin thickness was evaluated by modified Rodnan total skin thickness score (mRSS). Relationship between mRSS and prevalence or incidence of organ involvements was examined by logistic analyses. Correlation between mRSS and quantitative measurements of organ involvements was examined by correlation analyses and regression analyses. We recruited 198 patients into our study. The mean disease duration was 7.3 years with the mean follow-up duration of 3.2 years. Multivariate logistic regression analyses revealed that higher mRSS is related to higher prevalence of interstitial lung disease (P < 0.05), restrictive impairment (P < 0.01), and diffusion impairment (P < 0.05) of the lung. Correlation analyses revealed mRSS negatively correlates with forced vital capacity (P < 0.001) and diffusing capacity (P < 0.001) of the lung. Correlation between longitudinal change of mRSS and that of forced vital capacity (P < 0.05) or diffusing capacity (P < 0.001) of the lung was also demonstrated. Skin thickness score significantly correlates with quantitative measurements of lung involvement in Japanese patients with SSc.

Sections du résumé

BACKGROUND
Previous studies have shown the relationship between higher skin thickness score and the existence of organ involvements in systemic sclerosis (SSc). Here, we firstly investigated the correlation between skin thickness score and quantitative measurements of each organ involvement in Japanese patients with SSc.
METHODS
All Japanese SSc patients hospitalized to our clinic for initial evaluation of SSc were selected. Skin thickness was evaluated by modified Rodnan total skin thickness score (mRSS). Relationship between mRSS and prevalence or incidence of organ involvements was examined by logistic analyses. Correlation between mRSS and quantitative measurements of organ involvements was examined by correlation analyses and regression analyses.
RESULTS
We recruited 198 patients into our study. The mean disease duration was 7.3 years with the mean follow-up duration of 3.2 years. Multivariate logistic regression analyses revealed that higher mRSS is related to higher prevalence of interstitial lung disease (P < 0.05), restrictive impairment (P < 0.01), and diffusion impairment (P < 0.05) of the lung. Correlation analyses revealed mRSS negatively correlates with forced vital capacity (P < 0.001) and diffusing capacity (P < 0.001) of the lung. Correlation between longitudinal change of mRSS and that of forced vital capacity (P < 0.05) or diffusing capacity (P < 0.001) of the lung was also demonstrated.
CONCLUSIONS
Skin thickness score significantly correlates with quantitative measurements of lung involvement in Japanese patients with SSc.

Identifiants

pubmed: 31138286
doi: 10.1186/s13075-019-1919-6
pii: 10.1186/s13075-019-1919-6
pmc: PMC6540426
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

129

Références

Arthritis Rheum. 2001 Mar;44(3):653-61
pubmed: 11263780
Am J Med. 1984 May;76(5):779-86
pubmed: 6372452
Arthritis Rheum. 2007 Jul;56(7):2422-31
pubmed: 17599771
J Rheumatol. 1995 Jul;22(7):1281-5
pubmed: 7562759
Ann Rheum Dis. 2018 Feb;77(2):212-220
pubmed: 29066464
J Dermatol. 2018 Feb;45(2):128-138
pubmed: 29226387
Arthritis Care Res (Hoboken). 2016 Feb;68(2):167-78
pubmed: 26806474
Arthritis Rheumatol. 2015 Dec;67(12):3256-61
pubmed: 26316389
Arthritis Rheum. 2000 Nov;43(11):2445-54
pubmed: 11083267
Arthritis Rheum. 2011 May;63(5):1255-64
pubmed: 21305508
Rheumatology (Oxford). 2010 Feb;49(2):271-80
pubmed: 19447770
Ann Rheum Dis. 2007 Jul;66(7):966-9
pubmed: 17234649
Ann Rheum Dis. 2010 Jan;69(1):193-7
pubmed: 19103636
Ann Dermatol. 2015 Feb;27(1):1-9
pubmed: 25673924
Intern Med J. 2007 Jul;37(7):485-94
pubmed: 17547726
Eur J Clin Pharmacol. 1991;41(4):313-6
pubmed: 1804645
Arthritis Rheum. 2005 Dec;52(12):3792-800
pubmed: 16320330
Lancet. 2016 Jun 25;387(10038):2630-2640
pubmed: 27156934
Gastroenterology. 1996 Jul;111(1):85-92
pubmed: 8698230
Ann Rheum Dis. 2011 Jan;70(1):104-9
pubmed: 20679474
Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii32-5
pubmed: 19487221
Semin Arthritis Rheum. 2017 Apr;46(5):625-631
pubmed: 27839742
Clin Exp Rheumatol. 2011 Jul-Aug;29(4):697-700
pubmed: 21813064
Arthritis Rheum. 1999 Nov;42(11):2372-80
pubmed: 10555033
Arthritis Rheum. 1990 Aug;33(8):1256-63
pubmed: 2390128
Ann Rheum Dis. 2015 Jun;74(6):1188-94
pubmed: 24442885
Rheumatol Int. 1994;14(3):91-4
pubmed: 7839076
J Dermatol. 2010 Jan;37(1):11-25
pubmed: 20175837
J Dermatol. 2010 Jan;37(1):42-53
pubmed: 20175839
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1731-9
pubmed: 24692361
Respir Investig. 2013 Jun;51(2):69-75
pubmed: 23790734
Am J Pathol. 2006 Sep;169(3):954-66
pubmed: 16936269
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18
pubmed: 28516167
Br J Rheumatol. 1989 Aug;28(4):281-6
pubmed: 2787182
J Thorac Imaging. 1992 Mar;7(2):30-45
pubmed: 1578524
Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S17-22
pubmed: 22244622
Nat Rev Rheumatol. 2010 Feb;6(2):112-6
pubmed: 20125179
Arthritis Rheum. 1989 Sep;32(9):1128-34
pubmed: 2775321
Arthritis Rheum. 2000 Nov;43(11):2437-44
pubmed: 11083266
Autoimmun Rev. 2018 Feb;17(2):155-164
pubmed: 29196241
Arthritis Rheum. 2009 Aug;60(8):2490-8
pubmed: 19644851
Arthritis Rheum. 2001 Aug;44(8):1841-7
pubmed: 11508437

Auteurs

Kazuki M Matsuda (KM)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Ayumi Yoshizaki (A)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan. yoshizakiay-der@h.u-tokyo.ac.jp.

Ai Kuzumi (A)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Takemichi Fukasawa (T)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Satoshi Ebata (S)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Shunsuke Miura (S)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Tetsuo Toyama (T)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Asako Yoshizaki (A)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Hayakazu Sumida (H)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Yoshihide Asano (Y)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Koji Oba (K)

Department of Biostatistics, School of Public Health, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Shinichi Sato (S)

Department of Dermatology, The University of Tokyo Graduate School of Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH